MarketCapExport financials
Adverum Biotechnologies (ADVM)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Adverum Biotechnologies Income Statement 2024-2011 | ADVM
Brief overview of profit and loss at Adverum Biotechnologies
This overview is based on financial performance over the past five years. According to figures from Adverum Biotechnologies, revenue changed from $250 thousand to $1 million over five years. The five-year change reached +300%, while CAGR stood at 32%. This pace points to rapid expansion of the business.
EBITDA changed from −67 million dollars to −136 million dollars (−102.3%). EBITDA underperformed the top-line trend. The EBITDA share of revenue changed from −26788.8% to −13550.6%. The increased EBITDA share is a positive sign.
Comparing the endpoints shows a move from −64.5 million dollars to −131 million dollars. The period ended with a larger loss than it began with.
Financial takeaway
Positive developments coexist with areas of weakness. The constructive conclusion rests on higher operating efficiency and a larger revenue base. The most visible risks are a narrow EBITDA buffer and declining net profitability. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Adverum Biotechnologies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
76.4 M | 17.8 M | 77.4 M | 173 M | 790 M | 666 M | 186 M | 347 M | 103 M | 155 M | 903 M | - | - | - |
Shares |
19.8 M | 10.1 M | 99.3 M | 98 M | 64.1 M | 64.1 M | 61.4 M | 43.7 M | 36.2 M | 25.9 M | 22.8 M | - | - | - |
Historical Prices |
3.86 | 1.77 | 0.78 | 1.76 | 10.8 | 11.5 | 3.15 | 3.5 | 2.9 | 9.52 | 54 | - | - | - |
Net Income |
-131 M | -122 M | -155 M | -146 M | -118 M | -64.5 M | -72.6 M | -56.1 M | -114 M | -47.5 M | -25.4 M | -5.28 M | -1.81 M | - |
Revenue |
1 M | 3.6 M | - | 7.5 M | - | 250 K | 1.61 M | 1.85 M | 1.46 M | 2.32 M | 572 K | 480 K | 30 K | - |
Cost of Revenue |
- | - | - | - | - | - | 100 K | 500 K | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | 2.32 M | 572 K | 480 K | 30 K | - |
Operating Income |
-139 M | -129 M | -157 M | -146 M | -118 M | -68.5 M | -78.1 M | -58.8 M | -115 M | -47.8 M | -24.4 M | -3.45 M | -1.82 M | - |
Interest Expense |
8.23 M | 5.75 M | - | - | - | - | 4.2 M | 2.7 M | 762 K | 370 K | 18 K | 73 K | 8 K | - |
EBITDA |
-136 M | -123 M | -151 M | -141 M | -114 M | -67 M | -71.3 M | -56.8 M | -53 M | -44.4 M | -24.2 M | -3.43 M | -1.82 M | - |
Operating Expenses |
140 M | 133 M | 157 M | 154 M | 118 M | 68.8 M | 74.7 M | 60.7 M | 56 M | 47.6 M | 25 M | 3.93 M | 1.85 M | - |
General and Administrative Expenses |
63.1 M | 55.1 M | 57.9 M | 64.4 M | 44.6 M | 28.4 M | 24.6 M | 20.9 M | 24.4 M | 22.1 M | 8 M | 1.78 M | 536 K | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Adverum Biotechnologies
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
23.5 M | 21 M | 20.9 M | 20.9 M | 20.9 M | 16.5 M | 10.1 M | 10.1 M | 10 M | - | 99.5 M | 99 M | 98.6 M | 98.4 M | 98.1 M | 98 M | 97.8 M | 97.5 M | 88.9 M | 80.2 M | 73.8 M | 67.3 M | 64.5 M | 63.7 M | 63.1 M | 63 M | 62.5 M | 62.4 M | 57.4 M | 49 M | 43.4 M | 43 M | 42.1 M | 41.8 M | 41.4 M | 35 M | 27.1 M | 25.9 M | 25.7 M | 25.6 M | 24.9 M | 22.8 M | 16.4 M | 3.67 M | 3.67 M | 3.67 M | 3.67 M | 3.67 M | - | - | - | - | - | - | - | - | - |
Net Income |
-47.7 M | -49.2 M | -47 M | -32.4 M | -30.5 M | -27.1 M | -32.9 M | -31.5 M | -29.1 M | - | -40.1 M | -43.8 M | -37.9 M | - | -38.4 M | -44.3 M | -28.4 M | - | -27.8 M | -29.2 M | -22.9 M | - | -16.1 M | -15 M | -14.5 M | -15.7 M | -21 M | -18.8 M | -17.2 M | -14.8 M | -13.8 M | -11.4 M | -16.1 M | -22.4 M | -14.3 M | -61.7 M | -15.4 M | -14.1 M | -14.1 M | -9.77 M | -9.51 M | -10.4 M | -8.26 M | -5.09 M | -1.66 M | -3.69 M | -813 K | -721 K | -49 K | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | 1 M | - | - | - | - | 3.6 M | - | - | - | - | 7.5 M | - | - | 7.5 M | - | - | - | - | - | 250 K | - | - | 70 K | 833 K | 493 K | 216 K | 461 K | 463 K | 463 K | 462 K | 488 K | 395 K | 307 K | 265 K | 960 K | 953 K | 203 K | 203 K | 203 K | 204 K | 135 K | 30 K | - | 30 K | 150 K | 300 K | - | - | - | - | - | - | - | - |
Operating Income |
-48 M | -49.9 M | -48.2 M | -34.4 M | -32.9 M | -29.2 M | -34.5 M | -33.1 M | -30.2 M | - | -41 M | -44 M | -38.1 M | - | -38.5 M | -44.5 M | -28.6 M | - | -28 M | -29.8 M | -23.8 M | - | -17.1 M | -16.1 M | -15.7 M | - | -23.5 M | -19.9 M | -17.9 M | - | -14.6 M | -12.1 M | -16.6 M | - | -14.5 M | -61.9 M | -15.5 M | - | -14.2 M | -9.88 M | -9.56 M | - | -7.94 M | -4.45 M | -1.61 M | - | -778 K | -705 K | - | - | - | - | - | - | - | - | - |
Interest Expense |
371 K | 664 K | - | 2.09 M | 2.41 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.15 M | 1.22 M | - | 1.26 M | 1.09 M | 746 K | - | 742 K | 663 K | 489 K | - | 206 K | 222 K | 116 K | - | 117 K | 116 K | 52 K | - | 18 K | 4 K | 14 K | - | 28 K | 20 K | - | - | - | - | - | - | - | - | - |
EBITDA |
-46.3 M | -48.6 M | -47.5 M | - | - | -28.2 M | - | - | -28.6 M | - | -36.2 M | -41 M | -36.7 M | - | -35.2 M | -42.2 M | -27.5 M | - | -26.8 M | -28.5 M | -23.2 M | - | -16.7 M | -15.7 M | -15.3 M | - | -23.1 M | -19.4 M | -17.5 M | - | -14.1 M | -11.5 M | -16.1 M | - | -14.1 M | -61.6 M | -15.2 M | - | -14 M | -9.74 M | -9.44 M | - | -7.89 M | -4.43 M | -1.6 M | - | -771 K | -698 K | - | - | - | - | - | - | - | - | - |
Operating Expenses |
48 M | 49.9 M | 48.2 M | 35.4 M | 32.9 M | 29.2 M | 34.5 M | 33.1 M | 33.8 M | - | 41 M | 44 M | 38.1 M | - | 38.5 M | 44.5 M | 36.1 M | - | 28 M | 29.8 M | 23.8 M | - | 17.3 M | 16.1 M | 15.7 M | 16.8 M | 24.3 M | 20.4 M | 18.2 M | 16.1 M | 15 M | 12.6 M | 17 M | 23.9 M | 14.9 M | 62.2 M | 15.8 M | 15.1 M | 15.2 M | 10.1 M | 9.76 M | 10.6 M | 8.14 M | 4.59 M | 1.64 M | 1.93 M | 808 K | 855 K | 342 K | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
9.11 M | 12.7 M | 19.5 M | 15 M | 15.8 M | 13.8 M | 13.8 M | 12.5 M | 12.8 M | - | 17.2 M | 13.8 M | 15.2 M | - | 14.5 M | 21.9 M | 16.2 M | - | 11.4 M | 10.6 M | 9.04 M | - | 7.39 M | 7.13 M | 5.58 M | - | 4.83 M | 9.18 M | 5.37 M | - | 4.76 M | 4.06 M | 7.99 M | - | 6.15 M | 5.11 M | 8.32 M | - | 7.63 M | 4.96 M | 4.14 M | - | 2.4 M | 1.49 M | 726 K | - | 258 K | 194 K | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Adverum Biotechnologies (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Schweiz
Canada
Germany
China
Israel
Australia
